OncoMatch/Clinical Trials/NCT06482801
Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT
Is NCT06482801 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab for liver cancer.
Treatment: ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab — This trial is designed to investigate the safety, response rates and survival outcomes of patients with hepatocellular carcinoma by infusion of CTLA4, PD1 and PDL1 antibodies combination with chemodrug or/and bevacizumab through intra-tumor (IT).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: clinical trial agent or device
Patients participated in clinical trials of equipment or drugs (signed informed consent) within 4 weeks
Lab requirements
Blood counts
WBC ≥ 3.0×10E9/L; Hb ≥ 90g/L; PLT ≥ 50×10E9/L; INR < 2.3 or PT < 6 seconds above control; Impaired clotting test (platelet count < 60000/mm3, prothrombin activity < 50%) [excluded]
Kidney function
Cr ≤ 145.5 umul/L; Renal failure / insufficiency requiring hemo- or peritoneal dialysis [excluded]
Liver function
Child-Pugh class A or B/Child score > 7; Albumin > 28 g/L; Total bilirubin < 51 μmol/L
Child-Pugh class A or B/Child score > 7; WBC≥3.0×10E9/L; Hb≥90g/L； PLT ≥50×10E9/L；INR < 2.3 or PT < 6 seconds above control；Cr ≤ 145.5 umul/L；Albumin > 28 g/L；Total bilirubin < 51 μmol/L; Impaired clotting test (platelet count < 60000/mm3, prothrombin activity < 50%) [excluded]; Renal failure / insufficiency requiring hemo- or peritoneal dialysis [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06482801 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior clinical trial agent or device disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages